{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.88","upperLimit":"59.47","value":"48.92"},{"groupId":"OG001","lowerLimit":"46.55","upperLimit":"60.52","value":"59.01"},{"groupId":"OG002","lowerLimit":"39.10","upperLimit":"60.02","value":"50.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"157"}],"units":"Participants"}],"description":"Durability will be measured by determining the number of patients without recurrence of high-grade disease using results from urine cytology, cystoscopy, and biopsy of the bladder if clinically indicated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Carcinoma in situ (CIS) with or without concomitant high-grade Ta or T1 papillary disease","id":"OG000","title":"Carcinoma in Situ"},{"description":"Patients with high-grade Ta or T1 papillary disease (without concomitant CIS)","id":"OG001","title":"Papillary Disease"},{"description":"All patients","id":"OG002","title":"Total"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 60 Months","title":"Durability of Response During the Long-term Follow-up Period.","type":"SECONDARY","unitOfMeasure":"months"}